Follistatin-344 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Follistatin-344

Also known as: FS-344, FS344, Follistatin 344, FST344, Follistatin (344 aa isoform)

Endogenous glycoprotein / activin-binding protein; myostatin inhibitor

Research chemicalLast updated: October 19, 2026Based on 14 peer-reviewed studies

What it is

Follistatin-344 is a peptide people use for muscle building, primarily because it inhibits myostatin — the body's natural brake on muscle growth. It's studied for muscle wasting diseases and has been used off-label by athletes seeking physique enhancement. No FDA-approved use; prohibited by WADA; most evidence from animal models.

The scientific side

Follistatin-344 (FS-344) is a 344-amino-acid isoform of follistatin, a single-chain gonadal glycoprotein produced by alternative splicing of the follistatin gene (PMID 3153465, PMID 3380788, PMID 3365249). It acts as a specific activin-binding protein, neutralizing activin and thereby inhibiting pituitary follicle-stimulating hormone (FSH) release (PMID 3153465, PMID 3380788). Because myostatin (GDF-8) is a TGF-β superfamily member related to activin, follistatin also inhibits myostatin signaling; overexpression of follistatin in skeletal muscle suppresses Smad2 phosphorylation (a downstream myostatin signal) and activates Akt phosphorylation, resulting in myofiber hypertrophy and increased skeletal muscle mass. Follistatin also inhibits bone morphogenetic proteins (BMPs). The 344-amino-acid precursor form contains a heparin-binding domain that causes rapid tissue sequestration, resulting in a short systemic half-life after parenteral administration compared to engineered variants. Follistatin is expressed broadly across gonadal and extragonadal tissues including muscle, kidney, brain, pituitary, and vascular endothelium (PMID 1979488, PMID 8895365).

Class: Endogenous glycoprotein / activin-binding protein; myostatin inhibitor

Administration & storage

Administration
Subcutaneous injection into the abdomen (PMID: 32671599)
Storage
No storage conditions for FS344 are described in the reviewed abstracts.
Cautions
Black market FS344 products are frequently mislabeled or adulterated: only 9 of 17 tested products actually contained follistatin; others contained unrelated growth-promoting peptides such as MGF and GHRP-2.,All nine black market FS344 products that contained follistatin were His-tagged and contained a high degree of oligomers, raising concerns about product purity and immunogenicity.,High-dose subcutaneous FS344 injection was associated with central serous chorioretinopathy (CSCR) in 11 bodybuilding athletes; recurrent CSCR occurred in three patients with multiple injection histories.,Rigorous human safety data for FS344 are scarce and there is potential for serious harm; the compound is sold on the black market without regulatory oversight.,Sterile technique is essential when handling any injectable compound; no specific sterility data for FS344 formulations are available from the reviewed literature.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification. No approved pharmaceutical formulations of follistatin noted in reviewed literature.

WADA

Prohibited — listed under Chapter S4 of the WADA 2019 List of Prohibited Substances and Methods.

Health Canada

Not stated in reviewed literature — requires manual verification.